Munich-based biotech smartbax has held the first closing of a €4.7M Pre-Series A financing round led by Anobis Asset and Bayern Kapital, with participation from UnternehmerTUM Funding for Innovators, HTGF and Boehringer. The funding will support development of next-generation antibiotics targeting multi-drug resistant bacteria.
Comments
Want to join the conversation?
Loading comments...